CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT

CLINICAL TRIAL APPLICATION FOR OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE MONOHYDRATE NASAL SPRAY ACCEPTED BY NMPA

This announcement is made by CF PharmTech, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide shareholders and potential investors with an update on the Group's research and development progress.

INTRODUCTION

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the National Medical Products Administration of the PRC (the "**NMPA**") has issued a notice of acceptance (the "**Notice of Acceptance**") for the Group's clinical trial application for olopatadine hydrochloride and mometasone furoate monohydrate nasal spray (the "**Product**"), a fixed-dose combination independently developed by the Company. The relevant information is hereby announced as follows:

Product name	:	Olopatadine hydrochloride and mometasone furoate monohydrate nasal spray
Application type	:	Clinical trial for registration of domestically manufactured drugs
Acceptance number	:	CYHL2500215/CYHL2500214
Applicant	:	The Company
Indication for the application	:	Treatment of moderate-to-severe allergic rhinitis in adults and children aged 12 and older

KEY HIGHLIGHTS

The Product is a fixed-dose combination nasal spray independently developed by the Group. The acceptance of the clinical trial application marks the transition of this Product into the NMPA's regulatory review stage for potential clinical development.

The proposed indication covers moderate-to-severe allergic rhinitis in specified age groups. The Product combines an antihistamine and a corticosteroid in a single nasal spray. Through clinical studies, the Group intends to evaluate whether this fixed-dose combination can provide a convenient treatment option for patients who may not achieve satisfactory symptom control with monotherapy.

This milestone is aligned with the Group's strategy to build a differentiated respiratory and nasal portfolio and to leverage its formulation, device-integration and manufacturing capabilities in nasal drug–device combination products.

PRODUCT PROFILE AND CLINICAL RATIONALE

Allergic rhinitis is commonly managed with more than one mechanism of therapy, particularly in moderate-to-severe patients. The Product is designed as a fixed-dose combination delivered via a nasal spray suspension:

- Olopatadine hydrochloride: an antihistamine targeting histamine-related symptoms (e.g., sneezing and itching); and

- Mometasone furoate monohydrate: a corticosteroid targeting inflammation-related symptoms.

A fixed-dose combination may reduce the need for patients to use multiple products separately and may support convenience and adherence. Any such potential benefits remain subject to clinical validation and regulatory review.

STRATEGIC SIGNIFICANCE

The Company believes the advancement of this Product is significant for the following reasons:

- Portfolio expansion in rhinitis care: The Product, if successfully developed and approved, may contribute to the Group's allergy and rhinitis product line and broaden treatment options for moderate-to-severe patients (subject to approved labeling);

- Platform execution: Progress on this program reflects the Group's development capabilities in nasal suspension formulations and drug–device integration, which generally have higher technical and quality requirements than standard formulations; and

- Potential commercial synergies: Subject to approval and commercialization, the Product may be positioned alongside the Group's existing respiratory and nasal portfolio to enhance market coverage in airway disease therapies.

NEXT STEPS

The Company will continue to communicate and cooperate with the NMPA during the review process and will comply with applicable laws and regulations. Subject to regulatory review outcomes and any required approvals (as applicable), the Group will proceed with subsequent clinical development activities.

RISK WARNING

Pharmaceutical research and development is a lengthy and high-risk process. The development and commercialization of the Product involve significant uncertainties, including but not limited to clinical study outcomes, safety and efficacy results, regulatory review timelines and conclusions, manufacturing and quality requirements, and market competition. There is no assurance that the clinical trial application will result in commencement of clinical trials, successful clinical results, marketing approval, or successful commercialization.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company and to be aware of investment risks.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, December 17, 2025

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.